[Immunisation schedule of the Spanish Association of Paediatrics: 2014 recommendations]

Insights

The Spanish Association of Paediatrics

Area of Science:

  • Pediatrics
  • Immunology
  • Public Health

Context:

  • The Spanish Association of Paediatrics' Advisory Committee on Vaccines (CAV-AEP) annually updates childhood immunization schedules.
  • Schedules incorporate epidemiological data, vaccine safety, effectiveness, and efficiency.
  • Recommendations are categorized into routine, recommended, and risk group vaccinations.

Purpose:

  • To present the updated annual immunization schedule for children in Spain.
  • To provide evidence-based recommendations for vaccine administration timing and target populations.
  • To advocate for increased vaccine coverage and public availability.

Summary:

  • The updated schedule recommends MMR and varicella vaccines at 12 months (second dose at 2-3 years).
  • DTaP/Tdap vaccine is recommended at 4-6 years, with a Tdap booster at 11-12 years.
  • Meningococcal C vaccination is scheduled at 2, 12, and 12 years; pneumococcal vaccination is recommended routinely.
  • Human papillomavirus vaccination coverage needs enhancement.
  • Universal varicella vaccination in the second year of life is encouraged.
  • Rotavirus vaccination is recommended for all infants.
  • At-risk groups should be vaccinated against influenza and hepatitis A.
  • Meningococcal B vaccine is recommended for outbreak control.
  • Catch-up immunizations are emphasized.

Impact:

  • Aims to optimize child health outcomes through evidence-based vaccination strategies.
  • Promotes timely administration of critical vaccines to prevent infectious diseases.
  • Highlights the need for public health policies to ensure vaccine accessibility and coverage.
  • Contributes to the dynamic adaptation of immunization programs to evolving epidemiological landscapes.

Related Concept Videos

Vaccinations01:51

Vaccinations

Overview
44.1K
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
1.0K
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
408
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
967
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
410
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
554